

AFRICAN JOURNAL OF MEDICINE

and medical sciences

VOLUME 41 NUMBER 3

SEPTEMBER 2012



**Editor-in-Chief
O. BAIYEWU**

**Assistant Editors -in-Chief
O. O. OLORUNSOGO
B. L. SALAKO**

ISSN 1116-4077

Office based muscle biopsy using vacora vacuum assisted biopsy system

SN Akarolo-Anthony¹, TO OgunDIRAN², C Nkwodimmah², A Famooto², AS Famooto²

J Adediji², CN Rotimi⁴, W Balogun⁵, J Adeleye⁵ and CA Adebamowo^{3,6}

Department of Nutrition¹, Harvard School of Public Health, Boston MA 02115, Division of Oncology, Department of Surgery², University of Ibadan, University College Hospital, Ibadan, Nigeria, Department of Epidemiology and Public Health³, and Institute of Human Virology, University of Maryland, Baltimore MD 21201, Centre for Research on Genomics and Global Health⁴, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Department of Medicine⁵, University of Ibadan, University College Hospital, Ibadan and Office of Strategic Information, Research and Training, Institute of Human Virology⁶, Abuja, Nigeria

Abstract

Introduction: Muscle biopsy is a minor surgical procedure that has been conducted over several decades in clinical practice. Over the years, the technique to implement this procedure has been modified to make it easier to perform and more tolerable for the patient. This study aimed to assess the feasibility of muscle biopsy as an office based procedure, by using a vacuum Assisted Biopsy System.

Method: The procedure was successfully carried out on 57 individuals with/without diabetes, currently involved in the African American Diabetes Mellitus Study. One specimen was collected percutaneously from the vastus lateralis, under local anesthesia. A 16-gauge needle was used.

Results: Muscle biopsies were successfully carried out on all study participants. The study participants reported no complications after the procedure.

Conclusion: The findings from our study show that muscle biopsy can be feasibly implemented as an office based procedure, involving minimal muscle invasion, less trauma, hospital stay time, and expenses.

Keywords: Muscle, biopsy, vacora, vacuum, tissue

Abstract

Introduction: La biopsie musculaire est une procédure chirurgicale mineure qui a été menée pendant plusieurs décennies dans la pratique clinique. Au fil des ans, la technique pour la mise en œuvre de cette procédure a été modifiée pour la rendre plus facile à réaliser et plus supportable pour le patient. Cette étude vise à

évaluer la faisabilité de la biopsie musculaire comme une procédure de bureau, se servant d'un système de biopsie assisté par aspirateur.

Méthode: La procédure a été effectuée avec succès sur 57 personnes avec ou sans le diabète, actuellement impliqués dans l'étude du diabète sucré afro-américaine. Un spécimen a été recueilli par voie percutanée à partir du vaste externe, sous anesthésie locale. Une aiguille de calibre 16 a été utilisée.

Résultats: Des biopsies musculaires ont été effectuées avec succès sur tous les participants soumis à l'étude. Les participants soumis à l'étude n'ont rapporté aucune complication après l'intervention.

Conclusion: Les résultats de notre étude montrent que la biopsie musculaire peut en réalité être mise en œuvre comme une procédure de bureau, portant sur une invasion musculaire minimale, avec moins de traumatisme, une courte durée d'hospitalisation, et peu de dépenses

Introduction

Muscle biopsy is a relatively simple surgical procedure performed as part of standard of care in the management of many neuro-muscular and metabolic disorders. The procedure has evolved from open and semi-open biopsies to needle biopsies, which are now increasingly being used. Micro-biopsies, the use of fine-needles to obtain muscle biopsies is slowly gaining ground but its scope is limited by the small amount of tissue obtained and potential for tissue disruption. Muscle biopsies are also occasionally required for biomedical research into various diseases including Chronic Obstructive Pulmonary Disease [1], skeletal tumors [2], muscular dystrophies [3] nervous system diseases [4], diseases of the vascular system [5] and connective tissue [6]. In addition, given the importance of the muscle as a major metabolic tissue, muscle biopsies are also being done in metabolomics and proteomics research.

The type of muscle biopsy procedure depends on the indication and this has implication for the cost

and logistics involved in the procedure. Open biopsy is performed in the operating theatre through an incision that is about 4 cm long made over the skin of the muscle to be biopsied. After a biopsy is taken, the incision is closed with stitches. The Bergstrom technique [7] described as a semi-open biopsy [8], has been shown to achieve results similar to those obtained with open biopsy procedures [9,10]. This method combines the advantage of the "open-surgical" method with those of needle biopsy methods [11]. Needle biopsies may be performed in a ward or an office via incisions that may be as long as 1cm [12].

Open biopsies may be complicated by pain, bleeding, infection and muscle weakness. They are also more expensive than needle biopsies. Whereas needle biopsies are relatively safer, cheaper and quicker, it may not be possible to obtain adequate tissue materials from the procedure, particularly for gene expression and metabolic studies. Where open biopsies are done, patients stay in hospital for a few hours to allow monitoring. They have to wear dressing over the wound site and comply with instructions to keep the site as dry as possible. Open biopsies occasionally necessitate prolonged hospital stay with increased risk of acquiring nosocomial infections.

The complications of muscle biopsy are particularly troubling when the indication is for non-therapeutic research such as gene expression studies and metabolomics where participants do not derive any treatment benefit nor is the research likely to directly benefit them in the near future. This necessitated the search for alternative methods that will provide adequate amount of tissue samples while minimizing the risk to the research participant.

Materials and method

Study design

As part of a long-term strategy to understand the genetic basis of type 2 diabetes (T2D) in African ancestry populations, the African American Diabetes Mellitus (AADM) study [13] designed a study to obtain muscle biopsies from patients with T2D at varying levels of glycemic controls and normoglycemic individuals as control subjects. Prospective participants were enrolled at the Diabetes Clinic of the University College Hospital, Ibadan, Nigeria. They were counseled about the study, its aims and objectives and the fact that there is no direct therapeutic benefit for participants. Invited participants were asked to take the consent forms home for review and consideration, and to return to the clinic only if they wished to participate in the study. All individuals approached for muscle biopsy

consented to participate in the study having met inclusion criteria for the overall AADM study. All participants were asked about history of bleeding disorders, drug allergies and current medication especially anticoagulants and aspirin. Hematological tests to ascertain Prothrombin Time (PT) and Partial Prothromboplastin Time with Kaolin (PTTK) levels were carried out for all participants who consented to participate in the study.

Biopsy device

The biopsy procedure was performed with Vacora™ Vacuum Assisted Biopsy System – a compact, hand held system which is vacuum enabled to obtain large sample size using a minimally invasive technique [14]. It has the capacity to collect samples as large as 170mg in weight. A back pressure system ejects the sample and cleans the device.

Muscle biopsy procedure

The biopsy site used was the *vastus lateralis* muscle, in the anterior third of the thigh. This muscle was chosen because of its bulk, distance from major vascular structures, accessibility and redundancy, so that post-biopsy use will not be associated with significant pain. In addition, its ratio of fatty tissue to muscle is favorable, therefore the sample collected will have more muscular than fatty tissue. Throughout the procedure, every effort was made to ensure aseptis. First, we checked that the Vacora™ was in good working order by assembling it and turning on the power switch. We ensured all instruments to be used for the procedure such as a size 15 scalpel, sterile drapes, needles and syringes, methylated spirit, 1% local anesthetic with adrenaline, sterile gauze and skin preparatory agents are in place.


Study personnel educated participants on the biopsy procedure including what to expect during the process of obtaining tissue samples and associated risks such as post-procedure complications and follow up plan for pain assessment and complication management. Participants were required to fast for 8 hours before the procedure. Participants were given deep intramuscular injection of a 3rd generation cephalosporin in order to minimize the risk of infectious complications. Participants were asked to sit comfortably with knees flexed and thigh to be biopsied exposed. The skin over the biopsy site was prepared with methylated spirit and a sterile fenestrated drape placed over it. After 30 minutes, the skin, subcutaneous tissue and muscles were infiltrated with about 10 mls of 1% Xylocaine with adrenaline.

After waiting for 3–5 minutes, the site was tested for sensitivity to pain by applying deep pressure with a sterile needle to the site. After certifying the site to be insensitive to pain, a size 15 surgical blade was used to lance the skin in order to enhance penetration of the biopsy needle and the Vacora™ needle size 16G was inserted. The depth of insertion varied with body size and operator's judgment about placement of needle biopsy within the body of the muscle. The Vacora™ was switched on and held in place for about 30 seconds during which the biopsy was automatically obtained. The obtained sample was placed in a solution of Allprotect®. Gentle pressure was applied over the biopsy site for a few minutes to ensure that was no bleeding, after which the site was covered with a sterile band aid (Figure 1). Participants were observed in the office for 30 minutes after the biopsy and were surveyed about their experience of the procedure and the level of pain or discomfort felt during and after the procedure. The participants were instructed to remove the band aid after a few hours and were informed that they could resume normal activities shortly after the procedure. They were called on the phone 24 hours and 1 week after the procedure and asked questions about pain, bleeding and any other biopsy site complications they may have experienced.

of 34. All the participants tolerated the procedure well and all rated the immediate and 24 hours post procedure pain at 0. They all complained of mild discomfort at the beginning of the procedure during the infiltration of the skin with local anesthesia. There were no complications attributable to the procedure in the study population and no additional analgesic was required by any of the participants. The procedure was well tolerated and lasted an average of 12 minutes from the moment the participant was educated on the study procedure to the time he/she started completing the pain assessment questionnaire. RNA samples were subsequently extracted from all donated tissues and all but 2 (4%) were adequate for gene expression studies. A re-biopsy of the inadequate samples was not done. No complication was reported by any of the participants during the follow up period.

Discussion

Our study shows that an office based muscle biopsy using a vacuum assisted biopsy needle is capable of obtaining sufficiently large samples for research with minimal risk of pain and other complications to the participant. This is particularly important in situations where the research has no therapeutic intent and does not provide benefit for the participants in any direct manner. In such situations, researchers and ethics



Results

There were 39 (71%) male and 16 (29%) female participants with mean age of 48 years and mean BMI

committees compare the risk to participants with the potential beneficial knowledge that will be derived from the study – a so-called risk-knowledge calculus

[15,16]. The results of the gene expression studies have been presented elsewhere [17].

Prior to implementation of this study, we carried out extensive discussions with the institutional ethics committee in order to fully explain the rationale of the research, its risks and benefit and potential to contribute to scientific understanding of the metabolic derangements associated with diabetes mellitus. The need to search for and use the best minimally invasive technology available was considered an ethical imperative before approval for this study could be granted [18]. In addition, we discussed appropriate compensation for participants considering the invasive nature of the research and lack of therapeutic benefit. We found a balance that, in the judgment of the ethics committee was appropriate without constituting undue inducement according to the Nigerian National Code for Health Research Ethics [16].

In conclusion, an office based muscle biopsy technique using vacuum assisted biopsy needle generates adequate tissue sample for metabolic and gene expression studies while being associated with minimal risk of complications to the participants.

References

- Hayot M, Michaud A, Koechlin C, *et al.* Skeletal muscle microbiopsy: a validation study of a minimally invasive technique. *Eur Respir J* 2005;25:431-440.
- Aboulafia AJ and Malawer MM. Surgical management of pelvic and extremity osteosarcoma. *Cancer* 1993;71:3358-3366.
- Bushby K. Diagnosis and management of the limb girdle muscular dystrophies. *Pract Neurol* 2009;9:314-323.
- Finsterer J and Strobl W. Presentation, Etiology, Diagnosis, and Management of Camptocormia. *Eur Neurol*;64:1-8.
- Faulk WP, Labarrere CA, Pitts D and Halbrook H. Laboratory-clinical correlates of time-associated lesions in the vascular immunopathology of human cardiac allografts. *J Heart Lung Transplant* 1993;12:S125-134.
- Pestronk A, Schmidt RE and Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. *Muscle Nerve*;42:53-61.
- Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. *Am J Respir Crit Care Med* 1999;159:S1-40.
- Maltais F, LeBlanc P, Simard C, *et al.* Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996;154:442-447.
- Barreiro E, Gea J, Corominas JM and Hussain SN. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2003;29:771-778.
- Magistris MR, Kohler A, Pizzolato G, *et al.* Needle muscle biopsy in the investigation of neuromuscular disorders. *Muscle Nerve* 1998;21:194-200.
- Henriksson KG. "Semi-open" muscle biopsy technique. A simple outpatient procedure. *Acta Neurol Scand* 1979;59:317-323.
- Welker JA, Henshaw RM, Jelinek J, *et al.* The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. *Cancer* 2000;89:2677-2686.
- Rotimi CN, Dunston GM, Berg K, *et al.* In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study. *Ann Epidemiol* 2001;11:51-58.
- (Accessed at <http://bardbiopsy.com/products/vacora.php>.) last accessed, 20 Dec. 2010
- Deakin CT, Alexander IE, and Kerridge I. Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? *Mol Ther* 2009;17:1842-1848.
- National Health Research Ethics Committee of Nigeria. National Code for Health Research Ethics. In: Nigeria NHRECo, ed. Abuja, Nigeria: Federal Ministry of Health of Nigeria; 2006.
- Rotimi C. Type 2 Diabetes. In: Human Heredity and Health in Africa (H3Africa); 2011; Cape Town, South Africa: LOC, H3Africa Initiative; 2011.
- Emanuel EJ, Wendler D and Grady C. What makes research ethical. *JAMA* 2000;283:2701 - 2711.

Received: 30/06/11

Accepted: 26/07/12